PET Predicts Response to Head and Neck Cancer Treatment

Article

PET with F-18- fluorothymidine on patients with head and neck cancer prior to and during radiation therapy allows physicians assess early outcomes.

PET imaging with F-18- fluorothymidine on patients with head and neck cancer prior to and during radiation therapy allows physicians to assess early loco-regional clinical outcomes, according to a study published in the October issue of The Journal of Nuclear Medicine.

Studies have shown F-18-fluorodeoxyglucose (FDG) PET may be used to assess treatment response, but may produce false positives. Researchers from Kagawa University in Japan studied 28 patients with head and neck squamous carcinomas (HNSCCs) between May 2006 and September 2010, who underwent both FDG and F-18- fluorothymidine (FLT) PET imaging before treatment, at four weeks after the start of treatment and again five weeks after therapy was finished. Both primary and metastatic lesions were assessed. The researchers were looking for regions of focally increased metabolism, which were analyzed in relation to residual accumulation and local disease control.

Researchers found that during radiation therapy, F-18-FLT uptake accumulation disappeared in 34 of 54 lesions (63 percent) and the negative predictive value was 97 percent. The negative predictive value for the F-18-FDG uptake was 100 percent, and only nine lesions (16 percent) in all showed complete absence of accumulation.

“The specificity and overall accuracy of F-FLT PET were significantly higher than those of F-FDG PET both during and after RT,” wrote the authors. The high significance, the authors said, was due to the results of the evaluations of the primary lesions.

“With the development of new molecular imaging agents, it’s now up to clinical researchers to utilize them to assess the characteristics of malignant tumors and their therapeutic response to chemotherapy, radiotherapy, and molecular targeting therapy,” Hiroshi Hoshikawa, MD, the study’s lead author, said in a press release. “We hope that our findings will be helpful in understanding the significance of F-18-FLT-PET.”

Recent Videos
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
Related Content
© 2025 MJH Life Sciences

All rights reserved.